Could ANGLE plc See a Reversal After This Very Strong Session?

 Could ANGLE plc See a Reversal After This Very Strong Session?

The stock of ANGLE plc (LON:AGL) is a huge mover today! The stock increased 7.69% or GBX 4.5 on November 4, hitting GBX 63. About 153,471 shares traded hands or 9.11% up from the average. ANGLE plc (LON:AGL) has declined 14.39% since April 6, 2016 and is downtrending. It has underperformed by 15.48% the S&P500.
The move comes after 7 months positive chart setup for the GBX 47.13M company. It was reported on Nov, 4 by Barchart.com. We have GBX 117.18 PT which if reached, will make LON:AGL worth GBX 40.53M more.

More notable recent ANGLE plc (LON:AGL) news were published by: Marketwired.com which released: “Angle PLC: Barts Research Supports Potential Use of Parsortix” on November 04, 2016, also Marketwired.com with their article: “ANGLE plc: Notice of GM” published on November 01, 2016, Marketwired.com published: “ANGLE plc: Annual Report and Accounts and Notice of AGM” on September 09, 2016. More interesting news about ANGLE plc (LON:AGL) were released by: Marketwired.com and their article: “Angle PLC Announces New Publications Utilising Parsortix” published on April 29, 2016 as well as Marketwired.com‘s news article titled: “ANGLE PLC: Research Published in Clinical Chemistry” with publication date: September 30, 2016.

ANGLE plc is a holding company. The Company’s principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The company has a market cap of 47.13 million GBP. The Firm is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. It currently has negative earnings. The Company’s Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells from blood.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment